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N-LINKED GLYCOSYLATION AT POSITION ASN98 OF  
THE ALK1 RECEPTOR PROTEIN: 
RELEVANCE FOR ALK1 FUNCTION AND HHT PATHOGENESIS 
 
ERICK GADALETA 
ABSTRACT 
 Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic 
disorder that results from a mutation of one of two key signaling receptors for the 
transforming growth factor beta (TGFβ) superfamily: endoglin and activin receptor-like 
kinase 1 (ALK1). These mutations result in development of HHT Type 1 and HHT Type 
2, respectively. Patients suffering from HHT experience spontaneous blood vessel growth 
that can lead to telangiectasia, arteriovenous malformation (AVM) development, and 
other related health problems.  
 ALK1 is a serine/threonine kinase receptor found on the cell membrane of 
endothelial cells. ALK1 and its co-receptor endoglin, are activated by binding to the 
circulating BMP9 ligand. The ALK1-endoglin-BMP9 complex will then regulate 
endothelial proliferation by activating the SMAD pathway by phosphorylation. Mutations 
in the ACVRL1 gene can form a modified ALK1 protein that has a high potential to 
inhibit this function, causing the hyperproliferation of endothelial cells and the 
development of AVMs, and ultimately HHT Type 2.  
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 It is believed, however unproven, that ALK1 is heavily glycosylated in the 
extracellular domain. My thesis research was aimed at studying the glycosylation of 
ALK1 and at exploring the relevance of this glycosylation to the development of HHT. 
The glycosylation of ALK1 was investigated by using: (i) a computational prediction 
approach (NetNGlyc 1.0 bioinformatics server), (ii) a glycosylation inhibiting drug 
(tunicamycin), (iii) an in vitro enzymatic approach of glycosylation breakdown, and (iv) 
site-directed mutagenesis to identify the ASP residue glycosylated on ALK1.  
 The bioinformatics software NetNGlyc predicted a N-linked glycosylation site on 
an asparagine (ASN) residue located at position 98 in the extracellular domain of ALK1. 
I further found that, based on western blot analysis, ALK1 proteins shifted to a lighter 
molecular weight (5-8 kDa) when treated with tunicamycin, as well as endo H and 
PNGase F enzymes, which represent two glycosidases able to remove N-linked 
oligosaccharides on proteins. Western blot analysis also revealed an identical shift in 
protein size (5-8 kDa) when comparing wild type ALK1 to an asparagine98-to-alanine 
(N98A) mutant ALK1 construct. 
 The 5-8 kDa shift observed in the drug and enzymatic experiments indicate the 
removal of a bulky oligosaccharide from the wild type ALK1 protein. This 5-8 kDa shift 
observed in the mutagenesis experiment indicated that the same oligosaccharide addition 
could not occur on ALK1 when ASP98 was missing. Thus proving that the asparagine at 
the 98th position of ALK1 is involved in N-linked glycosylation. These important 
findings on ALK1 modification offer a greater understanding of the mechanisms behind 
ALK1 regulation and function, especially its role in controlling angiogenesis. 
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Furthermore, this data provides grounds for further research into the importance of ALK1 
glycosylation in the pathogenesis of HHT, as well as the investigation into new treatment 
regiments.  
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INTRODUCTION 
 
 Hereditary Hemorrhagic Telangiectasia (HHT) or also known as Osler-Weber-
Rendu disease is an autosomal dominant genetic disorder that is characterized by vascular 
malformations; due to increased angiogenesis and endothelial cell hyperproliferation 
(Dupuis-Girod, Bailly, & Plauchu, 2010). Patients suffering from HHT can experience 
recurrent nosebleeds, mucocutaneous/gastrointestinal telanciectases, and arteriovenous 
malformations (AVMs), which increase in frequency with age (Dupuis-Girod et al., 
2010). The phenotype and genotypes of HHT are well known and have been heavily 
researched and well characterized in the past 10 years. However, little is know about the 
underlying molecular mechanisms and defects in cell signaling governing the etiology of 
HHT.   
 
1. HHT Epidemiology 
 HHT is not a common genetic disorder with a global prevalence of about 1 in 
5,000-8,000 people diagnosed (Abdalla & Letarte, 2006). However, this number varies 
regionally throughout the world. HHT is rarely reported in African nations, but is highly 
prevalent among European regions (Abdalla & Letarte, 2006). For example, the county of 
Fly in Denmark has a prevalence of 1:1641-7246, and the Haut Jura region of France of 
about 1:2351 (Abdalla & Letarte, 2006). The highest occurance of HHT belongs to the 
Afro-Caribbean populations of the Netherlands Antille islands of Bonaire and Curacao 
(Abdalla & Letarte, 2006). Indeed, 1 in 1331 inhabitants of the islands of Bonaire and 
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Curacao are affected with HHT, making this the highest prevalence in the world 
(Westermann, Rosina, de Vries, & Coteau, 2003). Westerman et al, believe that this high 
occurance of HHT in this remote location is due to a founder effect. A founder effect can 
occur when a small number of individuals establish a location and lose their genetic 
variance with each successive generation. It has been proposed that, a mutation that 
caused HHT was most likely introduced by a small population of colonists affected by 
this disease who settled in Bonaire and Curacao in the eighteenth or seventeenth century 
(Westermann et al., 2003). 
 
2. HHT Symptoms and Phenotype 
 Over 90% of patients with HHT experience some form of telangiectases, which 
are small vascular malformations that can develop into lesions and act as a source of 
bleeding (Begbie, Wallace, & Shovlin, 2003). Telangiectases are found most commonly 
within the nasal mucosa, which account for epistaxis that increase in frequency with age, 
change in climate, and strenuous activity (Folz et al., 2004). This reoccurrence of nose 
bleeding has been linked to irons deficiency and anemia among HHT patients (Begbie et 
al., 2003). The appearance of these mucocutaneous telangiectases (Figure 1) is the most 
obvious sign of HHT (but not limited to HHT) that affects 80% of patients (Begbie et al., 
2003). Mucocutaneous telanciectases vary in size and shape, and can be identified around 
the oral cavity, facial skin, and hands of patients (Folz et al., 2004). According to Folz et 
al. (2004) mucocutaneous telangiectases are less hemorrhagic than the nasal subtype, thus 
requiring less treatment.  
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 Symptoms such as gastrointestinal telangiectasia and AVMs develop later in life 
and affect smaller populations of HHT patients (Biegbe et al., 2003). However, these 
symptoms are of greater concern due to the risk of developing visceral lesions, 
hemorrhages, aneurisms and even stroke (Biegbe et al., 2003). Gastrointestinal (GI) 
telangiectasia can develop throughout the GI tract but are most commonly found on the 
stomach and duodenum and less so in the colon (Biegbe et al., 2003). According to 
Biegbe et al. (2003) approximately 1/3rd of HHT patients presenting GI telangiectasia can 
develop GI hemorrhages, which can contribute to iron deficiency and anemia.  
Figure	  1.	  	  Photos	  of	  mucocutaneous	  telangiectases.	  A)	  lips	  B)	  finger	  C)	  ear.	  Adapted	  from	  Dupuis-­‐Girod,	  Bailly,	  &	  Plauchu,	  2010.	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 AVMs (Figure 2A) are abnormal, thin-walled vessels between arteries and veins 
which will shunt blood away from capillary networks and cause a multitude of 
complications depending on the location of AVMs (Dupuis-Girod et al., 2010). AVMs 
can appear in the lungs as pulmonary arteriovenous malformations (PAVMs), liver as 
hepatic arteriovenous malformations (HAVMs), brain as cerebral arteriovenous 
malformations (CAVMs), and even the spinal chord in rare instances (Dupuis-Girod et 
al., 2010). PAVMs (Figure 2B) affect over 30% of patients with HHT, making it the most 
common malformation (Biegbe et al., 2003). Typically PAVMs can be asymptomatic; 
hence they tend to remain undiagnosed for many HHT patients. PAVMs form right to left 
shunts that allow pulmonary arterial blood to pass through the lungs without getting 
oxygenated, resulting in hypoxemia (Biegbe et al., 2003). The shunting effect of PAVMs 
also increases particulate matter in the systemic circulation by reducing the amount of 
blood that would get filtered by capillaries (Biegbe et al., 2003). About 30% of HHT 
patients will develop HAVMs (Figure 2C), however less than 1% of this population will 
report symptoms due to this pathology (Dupuis-Girod et al., 2010). There are primarily 
three combinations of shunting that can occur from HAVMs: hepatic artery to hepatic 
vein, hepatic artery to portal vein, portal vein to hepatic vein (Dupuis-Girod et al., 2010). 
These shunts can lead to a number of complications such as: high output cardiac failure 
(HOCF), biliary ischemia, portal hypertension, encephalopathy, and mesenteric ischemia 
(Dupuis-Girod et al., 2010). CAVMs (Figure 2D) affect 10-23% of HHT patients and are 
considered the most life threatening complication (Biegbe et al., 2003). CAVMs can lead 
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to headaches, seizures, ischemia of the surrounding tissue, stroke, and hemorrhaging 
events (Biegbe et al., 2003).  
 
 
 
 
Figure	  2.	  	  Illustrations	  and	  images	  of	  the	  types	  of	  AVMs.	  A)	  Illustration	  of	  an	  AVM,	  adapted	  from	  “Arteriovenous malformation (AVM) | Christine’s story | Mayfield Clinic,” n.d.	  	  B)	  MRI	  of	  a	  PAVM,	  adapted	  from	  radiologypics,	  2013.	  C)	  MRI	  of	  a	  HAVM,	  adapted	  from	  “Hereditary	  Hemorrhagic	  Telangiectasia:	  Diagnosis	  and	  Management	  -­‐	  American	  Family	  Physician,”	  n.d.	  D)	  MRI	  of	  a	  CAVM,	  adapted	  from	  “Examinations:	  MRI-­‐scan	  -­‐	  Neurovascular	  Center	  Antwerp”	  n.d.	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3. BMP9-ALK1-Endoglin Cell Signaling 
 
 Depending on the genes affected by mutations, three types of HHT were defined: 
HHT type 1 (HHT1), HHT type 2 (HHT2), and juvenile polyposis HHT (JP-HHT). These 
genes code for three key proteins of interest, which belong to a specific signaling 
pathway of the superfamily of circulating protein ligands known as transforming growth 
factor beta (TGFβ) (Abdalla & Letarte, 2006). TGFβs are responsible for regulating 
cellular proliferation, differentiation, migration and extracellular matrix formation 
(Abdalla & Letarte, 2006). A critical TGFβ for normal functioning of endothelial cells is 
Figure	  3.	  An	  illustration	  of	  the	  ALK1-­endoglin	  receptor	  complex	  and	  its	  ligand	  BMP9.	  The	  ALK1	  and	  endoglin	  receptors	  regulate	  genes	  involved	  in	  proliferation	  and	  differentiation	  of	  endothelial	  cells.	  This	  receptor	  complex	  signals	  intracellularly	  through	  the	  Smad1/5/8	  pathway.	  Adapted	  from	  Dupuis-­‐Girod	  et	  al.,	  2010.	  	  
	  7 
a ligand known as the bone morphogenetic protein 9 (BMP9). BMP9 is largely produced 
from the liver cells known as hepatocytes; however, the brain and lungs contribute to its 
production as well (Tillet & Bailly, 2015). This ligand will binds to and activates the 
activin receptor-like kinase 1 (ALK1). ALK1 (Figure 3) is a TGFβ type 1 
serine/threonine (SER/THR) kinase receptor found on the cell surface membrane, which 
forms a complex with BMP type-II receptor and activin type-II receptor (Scharpfenecker 
et al., 2007). The next crucial protein involved in vascular quiescence and HHT is 
ALK1’s co-receptor endoglin. Endoglin (Figure 3) is a protein forming a disulfide-linked 
homodimer and possessing a heavily glycosylated extracellular domain (Tillet & Bailly, 
2015). There are three main sites of glycosylation on endoglin, and the possession of all 
three oligosaccharides regulates endoglin trafficking to the cell surface (Lux, Gallione, & 
Marchuk, 2000). The main purpose of endoglin is to increase the binding affinity of 
ALK1 to its ligand BMP9 (Tillet & Bailly, 2015). The ALK1-endoglin complex regulates 
endothelial proliferation and differentiation by activating the Smad pathway (Tillet & 
Bailly, 2015). 
 The signaling pathway starts with the binding of ALK1 to its ligand BMP9 
(Abdalla & Letarte, 2006). This bond activates BMP type-II and activin type-II receptors 
that phosphorlyate and activate ALK1, which will recruit the Smad proteins 1, 5, and 9 
(Figure 3) to become phosphorylated (David, et al., 2007). The now activated phospho-
Smad1/5/9 proteins bind to and activate Smad4, which then translocates to the nucleus to 
exert effects by activating and deactivating the appropriate genes to yield vascular 
quiescence (Abdalla & Letarte, 2006). This BMP9-ALK1-endoglin signaling pathway is 
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highly and predominantly expressed in endothelial cells and mutations in the receptors or 
its ligand result in HHT and vascular defects.  
 
4. Genotype 
 A coding gene mutation has the potential of changing the polarity, charge, 
hydrophobicity, and/or size of an amino acid. This typically, but not always, results in the 
creation of a misfolded or unstable protein that loses function due to the compromise in 
its structural integrity. There are three main forms of HHT; each type involves a mutated 
form of ALK1, endoglin, or Smad4 (Dupuis-Girod et al., 2010). Recent genetic data also 
indicate that mutations in BMP9 cause a rare form of HHT-like vascular anomaly 
syndrome (Wooderchak-Donahue et al., 2013). 
 The first is HHT type 1 (HHT1), which is caused by mutations in the ENG gene 
located on chromosome 9 and which codes for endoglin (Dupuis-Girod et al., 2010). A 
defective endoglin protein has been proposed to cause a decrease in ALK1 binding 
efficacy with BMP9. This in turn would decrease Smad1/5/9 activity within the 
endothelial cell and cause AVMs. HHT1 typically result in haploinsufficiency, which 
causes reduced levels of functional proteins involved in vascular quiescence (Dupuis-
Girod et al., 2010). Nearly every mutation found on the ENG gene disrupts the 
extracellular region of the protein that interacts with ALK1 (Abdalla & Letarte, 2006). 
There have been 155 mutations discovered on ENG, and around 80% of these mutations 
result in a premature stop codon (nonsense mutation) that form a truncated protein 
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(Abdalla & Letarte, 2006). According to Abdalla and Letarte, another 14% (21 
mutations) result in a splice site defect that affects the proper translation of the endoglin 
protein.  
 HHT type 2 (HHT2) is caused by mutations of the ACVRL1 gene located on 
chromosome 12 that codes for ALK1 (Dupuis-Girod et al., 2010). There are over 120 
mutations associated with the ACVRL1 gene and roughly 53% of these are harmless 
missense substitutions (Abdalla & Letarte, 2006). Abdalla and Letarte report that the 
number of mutations in the remaining 47% are broken down as: 24 deletions, 13 
insertions, 16 nonsense, and 4 splice site mutations. The vast majority of these mutations 
(75%) take place on the intracellular region where the kinase domain is found (Abdalla & 
Letarte, 2006). Mutations in this domain can affect ALK1’s overall ability to 
phosporylate the Smad1/5/9 proteins, resulting in signal inactivation and possibly AVM 
development. HHT1 and HHT2 make up about 80-85% of the HHT cases globally, 
however, there are other gene mutations involved that result in HHT or HHT-like 
symptoms (Botella et al., 2015).  
 A minority of patients can have a mutation of the MADH4 gene that codes for the 
Smad4 protein (Gallione et al., 2010). A defect in Smad4 is expected to prevent signal 
transduction to the nucleus in order to control genes involved in endothelial proliferation 
and differentiation. However, an inactive Smad4 also causes other symptoms not 
characterized by typical HHT. Therefore, patients suffering from this mutation are often 
diagnosed with juvenile polyposis-HHT (JP-HHT) (Gallione et al., 2010). Patients with 
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JP-HHT often present symptoms from HHT, such as AVMs and telangictases, as well as 
symptoms from juvenile polyposis, such as reoccuring polyps throughout the GI tract 
(Gallione et al., 2010). 
 
5. Research Focus 
 The laboratory of Dr. Philippe Marambaud at the Feinstein Institute for Medical 
Research has largely been focusing on the study of HHT2 and ALK1 mutations. My 
research work in this thesis finds its rationale in the observation that two major ALK1 
isoforms with different molecular sizes exist. Our original hypothesis was that differences 
in ALK1 glysosylation might explain the presence of these two main isoforms of ALK1. 
ALK1 isoforms were identified by western blotting. Western blotting is a technique used 
to visualize specific proteins collected from cellular or tissue extracts. Protein samples 
are loaded into individual wells of a gel and are separated by size through a process 
called electrophoresis (Figure 4).   
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 I observed a double band pattern in the wild type form of ALK1, as well as an 
HHT-linked R411P ALK1 mutant (Figure 4A). This double band appearance was already 
observed back in 2010 when multiple ALK1 mutants were functionally analyzed for 
BMP9 binding (Figure 4B) (Ricard et al., 2010). This pattern is a result of two ALK1 
isoforms that differ in molecular weight. We hypothesized that the difference in 
molecular weight of these two ALK1 isoforms is due to post-translational modification. 
Figure	  4)	  AlK1	  band	  pattern	  from	  western	  blot	  analysis.	  A)	  Western	  blot	  results	  showing	  a	  double	  band	  pattern	  for	  wild	  type	  ALK1	  proteins	  as	  well	  as	  a	  double	  band	  pattern	  for	  ALK1	  R411P	  mutant.	  R411P	  is	  a	  mutation	  found	  in	  an	  HHT	  family,	  which	  compromises	  the	  intracellular	  kinase	  domain	  of	  ALK1	  by	  replacing	  the	  arginine	  residue	  at	  the	  411	  position	  with	  a	  proline.	  Cells	  were	  transfected	  with	  vectors	  encoding	  HA-­‐tagged	  WT-­‐ALK1	  or	  ALK1	  R411P	  mutant.	  The	  cell	  lysates	  were	  resolved	  in	  10%	  SDS-­‐PAGE	  and	  immunoblotted	  with	  HA	  antibodies	  (see	  Methods).	  B)	  ALK1	  double	  band	  pattern	  confirmed	  along	  with	  multiple	  mutant	  isoforms	  (R479Q,	  R485F,	  I485F),	  adapted	  from	  Richard	  et	  al.,	  2010.	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Post-translational modification is the process of attaching functional groups to a newly 
synthesized protein. Two common types of modification that can lead to the observed 
changes in molecular weight (Figure 4) are glycosylation and phosphorylation.  
 Glycosylation refers to the formation of a glycoprotein via the covalent binding of 
a carbohydrate to an amino acid side chain of the immature protein. Carbohydrate side 
chains can be branched or straight, and are mostly composed of smaller sugar units such 
as: Mannose, galactose, N-acetylglucosamine, and sialic acid (Ham, 2011). The 
carbohydrate side chains have multiple functions. They can help determine the protein’s 
final structural conformation, as well as play a crucial role for cell-to-cell recognition 
(Ham, 2011). The most conserved function for attaching a carbohydrate to a protein is to 
direct the newly formed glycoprotein to the cell surface to either become incorporated 
into the cell membrane, or secreted from the cell. The type of bond formed between the 
carbohydrate and an amino acid side chain determines whether the glycosylation is N-
linked or O-linked (Ham, 2011). N-linked glycosylation refers to a carbohydrate binding 
to the exposed nitrogen atom of an amino acid, such as asparagine (ASN) (Ham, 2011). 
An ASN providing the linkage must be found within a three residue long “consensus 
sequence” in the proteins primary structure (Ham, 2011). The sequence is as follows: 
ASN, XXX (denoting any residue except proline), SER/THR (Ham, 2011). O-linked 
glycosylation refers to a carbohydrate binding to an oxygen atom on the hydroxyl group 
of either a serine (SER) or threonine (THR) residue (Ham, 2011).  
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 Phosphorylation refers to the formation of a phospho-protein via the covalent 
binding of a phosphate group to an amino acid side chain of a newly formed protein. A 
significant difference with this type of modification is that the covalent binding of the 
phosphate is reversible, which is key for its function (Lehmann, 2010). The addition of 
phosphates are catalyzed by kinase enzymes, and the removal of phosphates are catalyzed 
by phosphatases (Lehmann, 2010). Phosphorylation plays a major role in cell signaling 
and signal transduction by switching the activity of proteins via phosphate addition or 
removal (Lehmann, 2010). Bulky phosphate groups have the ability to change protein 
structure; which can either deactivate a protein by disrupting its structural motif or 
activating it by making it more stable to enable noncovalent interactions with a specific 
target protein (Lehmann, 2010). Reversible modification sites for phosphorylation can be 
found on SER, THR and tyrosine (TYR) (Lehmann, 2010). 
 
6. Purpose of Study 
	   ALK1 presents a potential for post-translational modifications, which can be 
demonstrated by western blot patterning (Figure 4 and Ricard et al., 2010). Since the 
addition of carbohydrates represents an important form of post-translational modification, 
the purpose of this study was to examine whether glycosylation can explain the presence 
of the two main isoforms observed for ALK1. Confirming the presence of 
oligosaccharides on ALK1 can provide a better understanding of the regulation and 
trafficking of this receptor. This will be executed by observing molecular weight changes 
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of ALK1 through pharmacological treatments and enzymatic digestion. The precise 
location of the attached oligosaccharide and the effects of glycosylation on receptor 
function will be investigated by developing tools such as mutant ALK1 constructs that 
prevent the addition of oligosaccharides on the protein.  
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METHODS  
 
1. Bioinformatic Analyses   
 The primary sequence (in FASTA format) for Homo sapiens ALK1 (entry 
#P37023) was obtained from UniProt (http://www.uniprot.org), which is a 
comprehensive database of protein sequences and functional information. The FASTA 
sequence for the whole ALK1 protein (signal peptide, extracellular domain, 
transmembrane domain, cytoplasmic domain) was input into a N-linked glycosylation 
prediction program called NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/).  
 The conservation of the human ALK1 N-linked glycosylation “consensus 
sequence” ASN-XXX-SER/THR (XXX for any amino-acid except proline, and 
SER/THR for SER or THR) was compared to that of mouse ALK1. The primary 
sequences of Homo sapiens ALK1 (entry #P37023) and Mus musculus ALK1 (entry 
#Q61288) was obtained from UniProt. The FASTA sequences for the extracellular 
domains of Homo sapiens ALK1 and Mus musculus ALK1 was input into LALIGN 
program (http://embnet.vital-it.ch/software/LALIGN_form.html) for comparison.  
 
2. Cell Culture and Transfection 
 All experiments performed involved the use of mouse-derived (murine) C2C12 
myoblasts (obtained from ATCC). The C2C12 cells were grown in 100-mm plates 
containing DMEM (Delbecco’s Modified Eagle Medium, Gibco®) and 10% FBS (Fetal 
Bovine Serum, Gibco®), as well as penicillin and streptomycin antibiotics (Gibco®). 
Once the C2C12 cells reach ~90% confluence, the cells were re-suspended using 1 mL of 
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0.25% Trypsin-EDTA (ethylenediaminetetraacetic acid) solution (Gibco®), which 
degrades extracellular proteins involved in cell-cell adhesion and cell adhesion to the 
plate. Cells were then plated in either 6-well or 12-well plates. Twenty-four hours after 
plating, the cells were transfected with either wild type (WT) ALK1, mutant (N98A and 
N98S) ALK1, or with empty vector (pcDNA3.1) cDNA for use as a negative control. The 
cDNA constructs were obtained through collaboration with Dr. Sabine Bailly (INSERM, 
CEA, Grenoble, France). 
 For Transfection, cDNA-liposome complexes were prepared in Opti-MEM™ 
(Gibco®) as per the manufacturer’s instructions (lipofecatmine® 2000, Invitrogen). 
Briefly, Opti-MEM™ solutions contained cDNA ranging in concentrations from 0.2-1.0 
µg and Lipofectamine® 2000 ranging from 3-4 µL per well. Opti-MEM™ solutions were 
incubated for 5 minutes in order to form the cDNA-liposome complex. 100 µL of the 
cDNA-liposome solutions were administered on top of the wells (containing the cells and 
conditioned medium) in a drop-wise fashion. The plate was incubated for 6 hours at 
37°C. 
 
3. Tunicamycin Treatment and In Vitro Deglycosylation  
 Four hours post-transfection, cells were treated with 1.0 µg/mL Tunicamycin 
(Cayman Chemical). Once the tunicamycin was administrated, the cells were placed back 
into the incubator (37° Celsius) for 16 hours. The cells were prepared for protein 
extraction as follows: Conditioned medium was removed and cells were washed gently 
with 1.0 mL of DPBS+Ca2+ (Dulbecco’s Phosphate Buffered Saline, Corning Cellgro®). 
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DPBS was removed and the 12-well plate of cells was placed on ice for cell 
homogenization and protein extraction. 
 The PNGase F Protocol and Endo H/Endo Hf Protocol was performed on protein 
extracts according to the New England Bio Lab Inc. recommended instructions (“Endo 
H/Endo Hf Protocol | NEB,” n.d.) (“PNGase F Protocol | NEB,” n.d.). Samples were 
incubated for 1 hour with their respective endoglycosidase.  
 
4. Extraction 
 The treated cells were extracted by using 100 µL of 1x RIPA lysis buffer 
(Millipore®) supplemented with protease inhibitors (PI) (Complete®) and incubated for 
10 minutes at 4°C. The lysed cells were re-suspended with a rubber scrapper, collected, 
and sonicated briefly to thoroughly disrupt cell membranes. The samples were spun down 
at 10,0000 RPM for ten minutes in order to remove cellular debris, and the media from 
each sample was collected for protein assay, endoglycosidase treatment, or western blot 
analysis.  
 
5. Protein Assay 
 The protein concentration within each sample was determined by the 
bicinchoninic acid (BCA) method and was performed as per the manufacturer’s 
recommendations (Sigma-Aldrich®). The Biomate3 (Thermo Electron Corp.) machine 
was used to measure protein concentrations of each sample.  
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 After the protein concentrations were determined, 35 µL of 3X Laemmli Sample 
Buffer (188 mM Tris-HCL pH 6.8, 6% SDS, 30% glycerol, 0.1% bromophenol blue, and 
15% β-mercaptoethanol) was added to each sample, which were then boiled at 100°C for 
ten minutes to ensure all proteins are fully denatured for western blot analysis.   
 
6. Western Blot Analysis  
 Samples were loaded into 10% polyacrylamide gels and separated by molecular 
mass through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
The proteins were then transferred onto nitrocellulose membranes (Thermo Scientific). 
The transfer efficacy was assessed using Ponceau S Solution (Sigma®).  
 Membranes were then stained with antibodies specific to either ALK1 or actin 
proteins in the following way: The nitrocellulose membranes were incubated in a 5% 
milk protein solution for 1 hour to block non-specific binding of primary antibodies. The 
membranes were washed three times for 15 minutes with Tris-buffered saline plus tween 
(TTBS). Anti-HA-peroxidase 3F10 (Roche) rat primary antibodies, and anti-actin 
antibodies (BD Biosciences™ Cat: 612656) were used to probe the membranes. Both 
membranes were incubated at 4°C overnight.   
 The next morning the membranes were washed 3 times for 15 minutes each in 
TTBS. The membrane stained for actin was then probed with a secondary anti-mouse 
antibody (Affinity purified Antibody peroxidase labeled Goat anti-Mouse IgG liquid 
Conjugate (Cat. No. 474-1806)). HA primary antibodies are already conjugated with 
horseradish peroxidase (HRP), so they do not need secondary antibodies for detection. 
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The membranes were submerged into Pierce™ enhanced chemiluminescence (ECL) 
Western Blotting Substrate and visualized using X-ray film. 	  
 
7. Primer Design 
 The primary DNA sequence (in FASTA format) for Homo sapiens ACVRL1 gene 
(ID: 94) was obtained from PubMed (http://www.ncbi.nlm.nih.gov). The gene open-
reading frame was copied, beginning at the first start codon (ATGACC) to the stop 
codon, and was pasted into the Quickchange Primer Design program 
(http://www.genomics.agilent.com/primerDesignProgram).  
 Primer set (N98A) was designed to substitute ASN98 with alanine (ALA). The 
second primer set (N98S) was designed to substitute ASN98 with SER.  
 
8. Gene Amplification Via PCR 
 N98A and N98S forward and reverse primers were re-suspended in tris 
ethylenediaminetetraacetic acid (TE) Buffer. The two samples were prepared by 
following the Mutant Strand Synthesis Reaction (Thermal Cycling) protocol from the 
QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies Cat. # 200523-5).  
 Primer samples were placed into the PCR machine that cycled through 3 phases 
for 35 rounds. Phase 1 (denaturing) was set at 95°C for 30 seconds, phase 2 (annealing) 
was set at 71.8°C for 45 seconds, and phase 3 (extension) was set at 72°C for two 
minutes.  
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 1 µL of Dpn1 restriction enzyme was added to each amplified DNA sample 
(N98A, N98S) in order to eliminate unwanted parental (non-mutated) supercoiled 
dsDNA. The samples were then thoroughly mixed and immediately incubated at 37° 
Celsius for 1 hour.  
 
9. Transformation and DNA Prep 
  In order to grow bacterial colonies possessing the mutant DNA, The 
Transformation of Supercompetent SURE® 2 (Stratagene) Cells was performed 
according to the manufacturer’s recommended protocol for the mutant samples (Agilent 
Technologies Cat. # 200523).  
  Once bacterial colonies were established from overnight incubation, a colony 
from N98A and N98S bacteria was placed into separate tubes containing 3.0 mL of Lulia 
Broth+50 µg/mL of carbenicillin (Carb+) antibiotics. The bacterial solution was incubated 
at 37° Celsius for 5 hours. After which, the 3.0 mL bacterial solution was transferred into 
a beaker possessing 250 mL of Lulia broth+Carb+ for overnight growth at 37° Celsius.  
 In order to isolate large amounts of the mutant DNA from the bacteria, a 
HiSpeed® Plasmid Maxi Kit (QIAGEN) was performed following the manufacturers’ 
recommended protocol. 1.0 mL of N98A and N98S cDNA was obtained from the kit and 
tested for its concentration by using the Spectrophotometer ND-1000 machine 
(NanoDrop®).  
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RESULTS and DISCUSSION 
1. Bioinformatic Analyses  
1.1 N-linked glycosylation prediction on ALK1 
 The N-linked glycosylation program NetNGlyc is able to quantify the confidence 
of its predictions based on the location of the ASN of interest. The first factor necessary 
for a high prediction output is whether the ASN residue falls in a “consensus sequence” 
for N-linked glycosylation (“NetNGlyc: Notes on the prediction output,” n.d.). The 
second factor is whether the “consensus sequence” is found in the extracellular domain of 
the protein of interest or not.  
 
 
 
Figure	  5)	  Bioinformatic	  prediction	  for	  N-­linked	  glycosylation	  on	  ALK1.	  A)	  ALK1	  domains	  illustrated	  along	  with	  corresponding	  residues.	  Asparagine	  98	  (N98)	  is	  highlighted	  in	  red.	  B)	  NetNGlyc	  graph	  depicting	  N-­‐linked	  glycosylation	  based	  on	  the	  presence	  of	  a	  consensus	  sequence	  located	  in	  the	  extracellular	  region.	  Results	  generated	  in	  	  
http://www.cbs.dtu.dk/services/NetNGlyc/. 	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 NetNGlyc detected three ASN residues that have potential of linking with an 
oligosaccharide due to their appearance into a N-linked glycosylation “consensus 
sequence”. ASN98 residue (Figure 5) achieved the highest potential score for N-linked 
glycosylation. ASN98 was able to pass the prediction threshold due to its location on the 
extracellular domain of the ALK1 protein. Oligosaccharides typically attach to proteins 
that are destined for the cell surface, and are functionally important for cell 
communication (Hall, Cartwright, Fleming, & Schwalbe, 2011). Both of these 
characteristics are required for proper ALK1 function, which is why the NetNGlyc 
program offers a strong and logical prediction of a possible glycosylation at ASN98.  
1.2 ASN98 Conservation Between Human and Mouse ALK1 
 LALIGN is a program used to compare the primary sequence of a protein 
amongst two different species. The purpose is to observe how conserved a protein region 
of interest is amongst different species.  
 
 
 The alignment between Homo sapiens ALK1 and Mus musculus ALK1 shows 
that ASN98 and its N-linked glycosylation “consensus sequence” (ASN-VAL-SER) is 
Figure	  6)	  ASN98	  conservation	  between	  human	  and	  mouse	  ALK1.	  LALIGN-­‐generated	  alignment	  between	  Homo	  sapiens	  ALK1	  primary	  sequence	  along	  side	  Mus	  musculus	  (mouse)	  ALK1	  primary	  sequence.	  N-­‐linked	  glycosylation	  “consensus	  sequence”	  is	  outlined	  in	  red.	  Adapted	  from	  http://embnet.vital-it.ch/software/LALIGN_form.html.	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fully conserved amongst the two species (Figure 6). In general, a highly conserved region 
of interest is conserved during evolution (Savas, Kim, Ahmad, Shariff, & Ozcelik, 2004). 
Thus, ASN98 along with the N-linked glycosylation “consensus sequence” may serve a 
larger role in overall ALK1 receptor function. 
 
2. The Effect of Tunicamycin on ALK1-Transfected C2C12 Cells 
2.1 C2C12 cell Transfection 
  DNA transfection is a technique commonly used to express proteins of interest 
from cDNA constructs. This process utilizes synthetic liposomes (for instance, 
lipofectamine 2000) that interact spontaneously with cDNA constructs to form a lipid-
DNA complex (Felgner et al., 1987). The lipid-DNA complex is capable of fusing with 
the plasma membrane of tissue culture cells due to its non-polar nature. The result is a 
rapid uptake and expression of the cDNA coding for the protein of interest.  
 Mouse-derived C2C12 myoblasts are used for transfection in this study due to 
their possession of all necessary machinery required for synthetic cDNA transcription 
and translation. These cells are properly maintained in DMEM, which is a cell medium 
that contains all the typical amino acids, glucose, salts and vitamins (Brunner et al., 
2009). DMEM in supplemented with FBS (see Methods) to provide C2C12 cells essential 
nutrients and growth factors to support cell metabolism and proliferation.  
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2.2 Tunicamycin Background 
  
 Tunicamycin (Figure 7) was originally used as an antiviral treatment due to its 
ability to compromise viral membrane glycoproteins (Lehle & Tanner, 1976). Successive 
work with tunicamycin demonstrated that the drug has a powerful effect by blocking the 
attachment of oligosaccharides to ASN residues (Lehle & Tanner, 1976). 
 
 
 
 
 
 
Figure	  7)	  Tunicamycin	  molecular	  structure.	  Adapted	  from	  “Tunicamycin	  (CAS	  11089-­‐65-­‐9)	  || Cayman Chemical | Supplier,” n.d.	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2.3 Effect of Tunicamycin on ALK1 molecular size 
 
   
  
 	   The	  lack	  of	  immunoreactivity	  in	  extracts	  isolated	  from	  C2C12	  cells	  transfected	  with	  the	  empty	  vector	  (lanes	  1	  and	  2)	  indicates	  the	  specificity	  for	  ALK1	  detection	  in	  lanes	  3-­‐6	  (Figure	  8).	  The	  control	  group	  (WT	  ALK1)	  displays	  the	  typical	  double	  band	  pattern	  that	  has	  been	  seen	  in	  previous	  experiments.	  What	  is	  clear	  in	  Figure	  8	  is	  that	  the	  treatment	  group	  (WT	  ALK1+Tuni)	  presents	  a	  5-­‐8	  kDa	  shift	  in	  both	  ALK1	  bands	  to	  a	  lighter	  molecular	  weight,	  band	  A	  giving	  rise	  to	  band	  A’,	  and	  band	  B	  to	  band	  B’.	  This	  indicates	  that	  both	  ALK1	  isoforms	  possess	  at	  least	  one	  
Figure	  8)	  Western	  blot	  analysis	  of	  WT	  ALK1-­transfected	  cells	  treated	  with	  
tunicamycin.	  A)	  C2C12	  cells	  transfected	  with	  empty	  control	  vector	  in	  lanes	  1	  and	  2	  present	  no	  ALK1	  bands.	  Cells	  transfected	  with	  WT	  ALK1	  cDNA	  in	  lanes	  3	  and	  4	  present	  band	  A	  and	  band	  B.	  Cells	  transfected	  with	  WT	  ALK1	  then	  treated	  with	  tunicamycin	  in	  lanes	  5	  and	  6	  present	  band	  A’	  and	  band	  B’.	  B)	  Expression	  of	  actin	  under	  each	  condition,	  used	  as	  internal	  control.	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oligosaccharide;	  and	  that	  tunicamycin	  works	  as	  intended	  by	  preventing	  N-­‐linked	  glycosylation	  from	  occurring	  amongst	  the	  treated	  samples,	  resulting	  in	  lighter	  WT	  ALK1	  proteins.	  	  
3.	  The	  Effect	  of	  Endoglycosidase	  Enzymes	  on	  ALK1	  
3.1	  Endo	  H	  and	  PNGase	  F	  	   Endo-­‐β-­‐N-­‐acetylglucosaminidase	  H	  (endo	  H)	  and	  peptide-­‐N-­‐glycosidase	  F	  (PNGase	  F)	  are	  both	  part	  of	  a	  glycoprotein-­‐degrading	  enzyme	  class	  called	  endoglycosidase	  (Tarentino,	  Gomez,	  &	  Plummer,	  1985).	  Historically,	  endoglycosidase	  enzymes	  have	  been	  used	  to	  separate	  proteins	  from	  their	  sugar	  moieties.	  These	  enzymes	  have	  helped	  scientists	  determine	  specific	  oligosaccharide	  structures	  as	  well	  as	  how	  they	  affect	  protein	  function,	  protein	  sorting,	  targeting	  and	  compartmentalization	  (Trimble	  &	  Tarentino,	  1991).	  	  	   PNGase	  F	  and	  endo	  H	  both	  act	  on	  N-­‐linked	  glycosylation.	  PNGase,	  however,	  has	  a	  wider	  range	  of	  glycoprotein	  targets.	  PNGase	  F	  can	  effectively	  hydrolyze	  the	  amide	  nitrogen	  of	  any	  ASN-­‐linked	  glycan	  as	  long	  as	  the	  C-­‐	  and	  N-­‐	  terminal	  ends	  of	  ASN	  are	  contributing	  in	  peptide	  bonds	  (Trimble	  &	  Tarentino,	  1991).	  Endo	  H	  is	  considered	  more	  specific	  in	  that	  it	  hydrolyzes	  high-­‐mannose	  oligosaccharides	  (Trimble	  &	  Tarentino,	  1991).	  	  	   Based	  on	  the	  bioinformatic	  analysis	  and	  tunicamycin	  results,	  there	  is	  a	  strong	  indication	  that	  N-­‐linked	  glycosylation	  is	  at	  play	  with	  ALK1.	  If	  these	  highly	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specialized	  enzymes	  can	  shift	  the	  molecular	  weight	  of	  ALK1	  by	  the	  same	  degree	  (5-­‐8	  kDa),	  these	  results	  will	  further	  support	  the	  previous	  experimental	  evidence.	  	  
3.2	  In	  Vitro	  Deglycosylation	  of	  ALK1	  
	   	  	  	   	  
	   The	  control	  group	  (WT	  ALK1)	  displays	  the	  typical	  double	  band	  pattern	  (Figure	  9)	  that	  has	  been	  observed	  in	  previous	  experiments.	  The	  endoglycosidase	  enzymes	  behaved	  differently	  even	  though	  they	  both	  target	  N-­‐linked	  glycans.	  WT	  ALK1	  treated	  with	  endo	  H	  enzymes	  resulted	  in	  shifting	  the	  top	  band	  to	  a	  lighter	  molecular	  weight	  by	  5-­‐8	  kDa	  (Figure	  9,	  band	  B’).	  WT	  ALK1	  treated	  with	  PNGase	  F	  enzymes	  resulted	  in	  shifting	  the	  top	  band	  to	  a	  lighter	  molecular	  weight	  by	  5-­‐8	  kDa	  (Figure	  9,	  band	  A’).	  The	  fact	  that	  these	  enzymes	  were	  selective	  towards	  only	  one	  
Figure	  9)	  Western	  blot	  analysis	  of	  glycosylation	  breakdown	  with	  endo	  H	  and	  
PNGase.	  Control	  ALK1	  (CTRL,	  lane	  1)	  presents	  two	  bands	  (band	  A,	  band	  B).	  Treatment	  with	  endo	  H	  (+Endo	  H,	  lane	  2)	  resulted	  in	  the	  appearance	  of	  band	  A	  and	  the	  lighter	  band	  B’.	  Treatment	  with	  PNGase	  F	  	  (PNGase,	  lane	  3)	  resulted	  in	  the	  appearance	  of	  the	  lighter	  band	  A’	  and	  band	  B.	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ALK1	  isomer	  may	  indicate	  a	  difference	  in	  the	  carbohydrate	  structures	  linked	  to	  the	  ALK1	  isomers.	  Regardless	  of	  the	  differences	  amongst	  the	  endoglycosidase	  enzymes,	  the	  results	  strongly	  reinforced	  the	  evidence	  of	  N-­‐linked	  glycosylation	  of	  ALK1.	  	  
	  
4.	  Mutagenesis	  
	  	   The	  principle	  behind	  mutagenesis	  is	  to	  synthesize	  mutated	  proteins	  through	  the	  use	  of	  synthetic	  mutant	  cDNA	  constructs.	  The	  function	  and	  structure	  of	  these	  mutant	  proteins	  can	  be	  compared	  to	  the	  wild	  type	  version,	  or	  with	  other	  mutant	  proteins.	  	  	   My	  previous	  experiments	  provided	  convincing	  data	  that	  supports	  the	  idea	  of	  N-­‐linked	  glycosylation	  of	  ALK1	  (Figures	  7,	  8,	  9).	  The	  next	  challenge	  would	  be	  to	  pinpoint	  the	  actual	  site	  of	  carbohydrate	  linkage	  on	  the	  protein	  sequence.	  I	  used	  site-­‐directed	  mutagenesis	  in	  order	  to	  confirm	  the	  exact	  location	  of	  the	  residue	  responsible	  for	  N-­‐linked	  glycosylation.	  This	  was	  done	  by	  constructing	  two	  mutant	  ALK1	  proteins	  and	  observing	  their	  behavior	  on	  a	  western	  blot.	  	  
4.1	  Mutant	  ALK1	  Design	  	   The	  first	  mutant	  ALK1	  is	  N98A,	  which	  substituted	  the	  polar	  ASN98	  amino	  with	  a	  non-­‐polar	  alanine.	  In	  general,	  replacing	  a	  polar	  residue	  with	  a	  non-­‐polar	  residue	  can	  result	  in	  the	  disruption	  of	  the	  protein	  structure	  and	  possibly	  its	  function.	  My	  goal	  with	  designing	  N98A	  was	  to	  remove	  the	  nitrogen	  containing	  amino	  acid	  that	  is	  involved	  in	  carbohydrate	  linkage	  (ASN),	  and	  to	  disrupt	  the	  “consensus	  sequence”	  that	  is	  necessary	  for	  N-­‐linked	  glycosylation.	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   The	  second	  mutant	  ALK1	  is	  N98S,	  which	  replaced	  ASN98	  with	  SER.	  This	  construct	  was	  designed	  to	  resemble	  a	  specific	  ALK1	  mutation	  potentially	  involved	  in	  HHT	  pathogenesis.	  According	  to	  the	  HHT	  database	  provided	  by	  the	  University	  of	  Utah,	  an	  HHT	  family	  carries	  a	  mutation	  in	  the	  ACVRL1	  gene	  that	  results	  in	  a	  N98S	  substitution	  in	  ALK1	  (http://www.arup.utah.edu/database/ACVRL1/ACVRL1_welcome.php).	  If	  N98S	  proves	  to	  disrupt	  ALK1	  glycosylation	  in	  the	  extracellular	  domain,	  this	  may	  provide	  support	  for	  the	  importance	  of	  ALK1	  glycosylation	  on	  receptor	  function	  and	  its	  relevance	  for	  HHT	  pathogenesis.	  	  
4.2	  N98A	  Mutation	  Prevents	  ALK1	  N-­linked	  glycosylation	  
	   	   	   	  Figure	  10)	  Western	  blot	  analysis	  of	  WT	  ALK1	  vs.	  N98A	  mutant	  ALK1.	  A)	  C2C12	  cells	  transfected	  with	  control	  vector	  in	  lane	  1	  presents	  no	  ALK1	  bands.	  Cells	  transfected	  with	  WT	  ALK1	  cDNA	  in	  lanes	  2	  and	  3	  present	  band	  A	  and	  band	  B.	  Cells	  transfected	  with	  N98A	  ALK1	  in	  lanes	  5	  and	  6	  present	  band	  A’	  and	  band	  B’.	  B)	  Expression	  of	  Actin	  under	  each	  condition.	  
kDa	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 The result from the western blot comparing WT ALK1 with N98A ALK1 
(Figure 10) resembles that of the tunicamycin experiment (Figure 8). A 5-8 kDa 
difference is observed when comparing WT ALK1 and N98A ALK1 (Figure 10). The 
observable shift to a lighter molecular weight of the two N98A ALK1 isoforms are due to 
the absence of bulky oligosaccharides attaching to the alanine on the 98th position. The 
N98A mutant ALK1 experiment thus confirms that there is indeed a N-linked 
glycosylation on wild type ALK1, specifically at ASN98.  
4.3 N98S Mutation Results 
   
 Results from the western blot comparing WT ALK1 with N98S ALK1 display no 
observable difference in the molecular weight of N98S ALK1 (Figure 11). The lack of an 
Figure	  11)	  Western	  blot	  analysis	  of	  WT	  ALK1	  vs.	  N98S	  mutant	  ALK1.	  A)	  C2C12	  cells	  transfected	  with	  control	  vector	  in	  lane	  1	  presents	  no	  ALK1	  bands.	  Cells	  transfected	  with	  WT	  ALK1	  cDNA	  in	  lanes	  2	  and	  3	  present	  band	  A	  and	  band	  B.	  Cells	  transfected	  with	  N98S	  ALK1	  in	  lanes	  5	  and	  6	  present	  band	  A	  and	  band	  B.	  B)	  Expression	  of	  Actin	  under	  each	  condition.	  
kDa	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observable change in molecular weight indicates that replacing ASN98 with a SER 
residue does not produce an effective knockout for N-linked glycosylation. This may be 
due to an inadvertent creation of a new “consensus 
sequence.”
 
	  	  	  	  	  	  	  
The “consensus sequence” necessary for N-linked glycosylation is ASN-XXX-
SER/THR (see Methods). The sequence for WT ALK1 is ASN98-VAL99-SER100 and is 
represented in Figure 6. However, there is another asparagine residue located at the 96th 
position of WT ALK1. Therefore, replacing ASN98 with a SER residue may have 
compromised the original consensus sequence, but it also created a new sequence starting 
Figure	  12)	  Consensus	  sequence	  shift	  on	  ALK1.	  Wild	  type	  and	  N98S	  ALK1	  primary	  sequences	  are	  displayed.	  The	  consensus	  sequence	  in	  WT	  ALK1	  starting	  at	  N98	  is	  highlighted	  in	  red.	  The	  newly	  formed	  consensus	  sequence	  starting	  at	  N96	  in	  N98S	  ALK1	  is	  highlighted	  in	  red.	  Adapted	  from	  http://embnet.vital-it.ch/software/LALIGN_form.html	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at the 96th position (ASN96-HIS97-SER98) (Figure 12). This shifted consensus sequence 
seems to still retain the potential for N-linked glycosylation of N98S ALK1. Experiments 
aimed at substituting ASN96 to ALA are underway to test this hypothesis. 
 
5. Conclusion 
 In this thesis, I have shown that treating WT ALK1 with tunicamycin prevents N-
linked glycosylation, resulting in a lighter protein. I have demonstrated that 
endoglycosidase digestion removes N-linked carbohydrates on ALK1, which results in a 
lighter protein. Lastly, I demonstrated with a mutant construct that results in a 
substitution at ASN98 of ALK1 to ALA prevents N-linked glycosylation. This data is 
important because it unambiguously demonstrates for the first time that there is N-linked 
glycosylation at ASN98 on the ALK1 receptor protein. Glycosylation is a critical post-
translational modification for some proteins destined for the cell surface (Ham, 2011). 
My hypothesis is that N-linked glycosylation of ALK1 regulates the trafficking of this 
receptor to the cell membrane. In order to test this hypothesis, functional analysis must be 
performed on the N-glycosylation-defective ALK1 mutant N98A to test its signaling 
response to its physiological ligand BMP9 (see Introduction). Cell surface expression of 
N98A ALK1 will also have to be investigated. Even though N98S ALK1 remained 
glycosylated, due to its relation to HHT, it will also be interesting to determine whether 
this mutant of ALK1 is associated with functional defects. The best way of finding a 
treatment for a disease is by understanding the basic biology of proteins linked to the 
pathogenesis of this particular disease. In this context, the main objective of this thesis 
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was to increase our understanding of a novel mechanism of ALK1 regulation, i.e., N-
linked glycosylation. It is my expectation that these discoveries may lead towards further 
research aimed at identifying treatments for HHT patients. 
	  34 
 
REFERENCES 
 
 
Abdalla, S. A., & Letarte, M. (2006). Hereditary haemorrhagic telangiectasia: current 
views on genetics and mechanisms of disease. Journal of Medical Genetics, 
43(2), 97–110. http://doi.org/10.1136/jmg.2005.030833 
Arteriovenous malformation (AVM) | Christine’s story | Mayfield Clinic. (n.d.). 
Retrieved January 29, 2016, from 
http://www.mayfieldclinic.com/MC_hope/Story_sherri.htm 
Begbie, M. E., Wallace, G. M. F., & Shovlin, C. L. (2003). Hereditary haemorrhagic 
telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. 
Postgraduate Medical Journal, 79(927), 18–24. 
http://doi.org/10.1136/pmj.79.927.18 
Botella, L.-M., Albiñana, V., Ojeda-Fernandez, L., Recio-Poveda, L., & Bernabéu, C. 
(2015). Research on potential biomarkers in hereditary hemorrhagic 
telangiectasia. Frontiers in Genetics, 6. http://doi.org/10.3389/fgene.2015.00115 
David, L., Mallet, C., Mazerbourg, S., Feige, J.-J., & Bailly, S. (2007). Identification of 
BMP9 and BMP10 as functional activators of the orphan activin receptor-like 
kinase 1 (ALK1) in endothelial cells. Blood, 109(5), 1953–1961. 
http://doi.org/10.1182/blood-2006-07-034124 
D, B., J, F., H, A., H, S., W, P., & G, G. (2009). Serum-free cell culture: the serum-free 
media interactive online database. ALTEX, 27(1), 53–62. 
	  35 
Dupuis-Girod, S., Bailly, S., & Plauchu, H. (2010). Hereditary hemorrhagic 
telangiectasia: from molecular biology to patient care. Journal of Thrombosis and 
Haemostasis, 8(7), 1447–1456. http://doi.org/10.1111/j.1538-7836.2010.03860.x 
Endo H/Endo Hf Protocol | NEB. (n.d.). Retrieved March 25, 2016, from 
https://www.neb.com/protocols/2012/10/18/endo-hf-protocol 
Examinations: MRI-scan - Neurovascular Center Antwerp. (n.d.). Retrieved January 29, 
2016, from http://www.nvca.be/en/exams/mri_scan 
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., … 
Danielsen, M. (1987). Lipofection: a highly efficient, lipid-mediated DNA-
transfection procedure. Proceedings of the National Academy of Sciences, 84(21), 
7413–7417. 
Folz, B. J., Lippert, B. M., Wollstein, A. C., Tennie, J., Happle, R., & Werner, J. A. 
(2004). Mucocutaneous telangiectases of the head and neck in individuals with 
hereditary hemorrhagic telangiectasia -- analysis of distribution and symptoms. 
European Journal of Dermatology: EJD, 14(6), 407–411. 
Gallione, C., Aylsworth, A. S., Beis, J., Berk, T., Bernhardt, B., Clark, R. D., … 
Marchuk, D. A. (2010). Overlapping spectra of SMAD4 mutations in juvenile 
polyposis (JP) and JP–HHT syndrome. American Journal of Medical Genetics 
Part A, 152A(2), 333–339. http://doi.org/10.1002/ajmg.a.33206 
Hall, M. K., Cartwright, T. A., Fleming, C. M., & Schwalbe, R. A. (2011). Importance of 
Glycosylation on Function of a Potassium Channel in Neuroblastoma Cells. PLoS 
ONE, 6(4). http://doi.org/10.1371/journal.pone.0019317 
	  36 
Ham, B. M. (2011). Proteomics of Biological Systems. Hoboken, US: Wiley. Retrieved 
from http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10501256 
Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management - American Family 
Physician. (n.d.). Retrieved January 29, 2016, from 
http://www.aafp.org/afp/2010/1001/p785.html 
Lehle, L., & Tanner, W. (1976). The specific site of tunicamycin inhibition in the 
formation of dolichol-bound N-acetylglucosamine derivatives. FEBS Letters, 
71(1), 167–170. http://doi.org/10.1016/0014-5793(76)80922-2 
Lehmann, W. D. (2010). Protein Phosphorylation Analysis by Electrospray Mass 
Spectrometry. Cambridge, GB: Royal Society of Chemistry. Retrieved from 
http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10627755 
Lux, A., Gallione, C. J., & Marchuk, D. A. (2000). Expression analysis of endoglin 
missense and truncation mutations: insights into protein structure and disease 
mechanisms. Human Molecular Genetics, 9(5), 745–755. 
http://doi.org/10.1093/hmg/9.5.745 
NetNGlyc: Notes on the prediction output. (n.d.). Retrieved March 22, 2016, from 
http://www.cbs.dtu.dk/services/NetNGlyc-1.0/output.php 
PNGase F Protocol | NEB. (n.d.). Retrieved March 25, 2016, from 
https://www.neb.com/protocols/2014/07/31/pngase-f-protocol 
radiologypics. (2013, February 11). Pulmonary Arteriovenous Malformation. Retrieved 
from http://radiologypics.com/2013/02/10/pulmonary-arteriovenous-
malformation/ 
	  37 
Ricard, N., Bidart, M., Mallet, C., Lesca, G., Giraud, S., Prudent, R., … Bailly, S. (2010). 
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: 
a diagnostic tool for novel ACVRL1 mutations. Blood, 116(9), 1604–1612. 
http://doi.org/10.1182/blood-2010-03-276881 
Savas, S., Kim, D. Y., Ahmad, M. F., Shariff, M., & Ozcelik, H. (2004). Identifying 
Functional Genetic Variants in DNA Repair Pathway Using Protein Conservation 
Analysis. Cancer Epidemiology Biomarkers & Prevention, 13(5), 801–807. 
Scharpfenecker, M., Dinther, M. van, Liu, Z., Bezooijen, R. L. van, Zhao, Q., Pukac, L., 
… Dijke, P. ten. (2007). BMP-9 signals via ALK1 and inhibits bFGF-induced 
endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of Cell 
Science, 120(6), 964–972. http://doi.org/10.1242/jcs.002949 
Tarentino, A. L., Gomez, C. M., & Plummer, T. H. (1985). Deglycosylation of 
asparagine-linked glycans by peptide:N-glycosidase F. Biochemistry, 24(17), 
4665–4671. http://doi.org/10.1021/bi00338a028 
Trimble, R. B., & Tarentino, A. L. (1991). Identification of distinct endoglycosidase 
(endo) activities in Flavobacterium meningosepticum: endo F1, endo F2, and 
endo F3. Endo F1 and endo H hydrolyze only high mannose and hybrid glycans. 
Journal of Biological Chemistry, 266(3), 1646–1651. 
Westermann, C. J. J., Rosina, A. F., de Vries, V., & Coteau, P. A. de. (2003). The 
prevalence and manifestations of hereditary hemorrhagic telangiectasia in the 
Afro-Caribbean population of the Netherlands Antilles: A family screening. 
	  38 
American Journal of Medical Genetics Part A, 116A(4), 324–328. 
http://doi.org/10.1002/ajmg.a.10002 
Wooderchak-Donahue, W. L., McDonald, J., O’Fallon, B., Upton, P. D., Li, W., Roman, 
B. L., … Bayrak-Toydemir, P. (2013). BMP9 Mutations Cause a Vascular-
Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic 
Telangiectasia. The American Journal of Human Genetics, 93(3), 530–537. 
http://doi.org/10.1016/j.ajhg.2013.07.004 
 
	  39 
 
CURRICULUM VITAE 
 
Erick Gadaleta           9/14/1989 
176 Nassau Ave                                                                                               516-376-9757 
Manhasset, NY 11030                                                                                   erickg@bu.edu 
 
 
Education 
Boston University School of Medicine, Boston, MA                   
M.S Degree in Medical Sciences  (Anticipated May 2016)                                                                               
Union College, Schenectady, NY                      
Bachelor of Science in Biology, Minor in Psychology               
June 2012 
Deans List 2010-2011, Union College Presidential Scholarship 
Laboratory & Related Course Work 
Mutagenesis, DNA Transfection Micro Injection in mice, Cell fractioning, Western Blots, Cell 
culturing, Isolation and purification of genomic DNA, DNA Primer design, PCR, Proficient in 
IR, H1-NMR, and C13-NMR spectroscopy, Ion exchange chromatography, gel filtration 
chromatography, amplification refractory mutation system polymerase chain reaction (ARMS-
PCR), gel electrophoresis, SDS polyacrylamide gel electrophoresis (PAGE), biomechanics, 
neuroanatomy, neural-integration, EEG data analysis, fMRI data analysis. 
 
Laboratory Research 
Angiogenesis Research at The Feinstein Institute of Medical Research 
Focus was on repurposing FDA approved drugs for hereditary hemorrhagic telangiectasia 
therapy. Investigated glycosylation of the ALK1 receptor for the relevance of HHT2 pathology by 
the use of mutagenesis. Performed functional analysis of ALK1 mutants for ALK1 activity. 
 
Cancer Research at Tufts University School of Medicine 
Focus on genetic metastasis in breast and pancreatic cancer. Testing specific tumor cell lines for 
immunosuppressant activity in mouse host that correlates to later metastatic activity. My main 
responsibilities included antibody isolation and antigen identification for the purpose of 
improving chemotherapy specificity. 
Activities such as tumor imaging, off-label drug testing, cancer cell isolation and culturing, gene 
isolation by western blotting and PCR 
 
 
